4546 El Camino Real
Suite B1
Los Altos, CA 94022
United States
650 284 4433
https://renovorx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 8
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Ramtin Agah M.D. | Founder, Chairman of Board & Chief Medical Officer | 332.89k | N/D | 1966 |
Mr. Shaun R. Bagai | CEO, Secretary & Director | 589.38k | N/D | 1977 |
Ms. Leesa Gentry | Chief Clinical Officer | N/D | N/D | 1970 |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
La calificación ISS Governance QuickScore de RenovoRx, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.